[EN] IMIDAZOPYRIDINE DERIVATIVES AS BSR-3 ANTAGONISTS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE ANTAGONISTES DE BSR-3
申请人:BIOFOCUS DISCOVERY LTD
公开号:WO2005080390A1
公开(公告)日:2005-09-01
Compounds of the general formula (I): wherein X, Y, R and R’ are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament against BRS-3 receptor-related disorders.
[EN] DOPAMINE D2 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR D2 DE LA DOPAMINE
申请人:BROAD INST INC
公开号:WO2016100823A1
公开(公告)日:2016-06-23
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
Inhibition of insulin-regulatedaminopeptidase (IRAP) has been shown to improve cognitive functions in several animal models. Recently, we performed a screening campaign of approximately 10,000 compounds, identifying novel small-molecule-based compounds acting as inhibitors of the enzymatic activity of IRAP. Here we report on the chemical synthesis, structure-activity relationships (SAR) and initial